Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Cancer Retrieve available abstracts of 88 articles: HTML format

Single Articles

July 2022
1. FANG AM, Shumaker LA, Martin KD, Jackson JC, et al
   Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
   Cancer. 2022 Jul 12. doi: 10.1002/cncr.34355.
   PubMed     Abstract available
   
   
   
2. O'ROURKE K
   Can multiparametric ultrasound be used for prostate cancer?
   Cancer. 2022;128:2399.
   PubMed    
   
   
   June 2022
3. NNATE DA, Ball J
   Current prostate cancer screening and treatment strategies may not support a holistic nationwide program.
   Cancer. 2022 Jun 1. doi: 10.1002/cncr.34337.
   PubMed     Abstract available
   
   
   March 2022
4. MENDES AA, Lu J, Kaur HB, Zheng SL, et al
   Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
   Cancer. 2022 Mar 25. doi: 10.1002/cncr.34190.
   PubMed     Abstract available
   
   
   
5. O'ROURKE K
   Gut microbiome linked to aggressive prostate cancer.
   Cancer. 2022;128:938.
   PubMed    
   
   
   February 2022
6. MCDONALD AC, Gernand J, Geyer NR, Wu H, et al
   Ambient air exposures to arsenic and cadmium and overall and prostate cancer-specific survival among prostate cancer cases in Pennsylvania, 2004 to 2014.
   Cancer. 2022 Feb 23. doi: 10.1002/cncr.34128.
   PubMed     Abstract available
   
   
   January 2022
7. WITTMANN D, Mehta A, Bober SL, Zhu Z, et al
   TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results.
   Cancer. 2022 Jan 5. doi: 10.1002/cncr.34076.
   PubMed     Abstract available
   
   
   December 2021
8. TILBURT JC, Zahrieh D, Pacyna JE, Petereit DG, et al
   Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD).
   Cancer. 2021 Dec 10. doi: 10.1002/cncr.34062.
   PubMed     Abstract available
   
   
   
9. HAY A
   Stockholm3 tests improve prostate cancer screening.
   Cancer. 2021;127:4328-4329.
   PubMed    
   
   
   November 2021
10. JAVIER-DESLOGES J, Nelson TJ, Murphy JD, McKay RR, et al
    Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials.
    Cancer. 2021 Nov 22. doi: 10.1002/cncr.33991.
    PubMed     Abstract available
    
    
    
11. LIM JE, Huang J, Mnnist S, Weinstein SJ, et al
    Hair dye use and prostate cancer risk: A prospective analysis in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort.
    Cancer. 2021 Nov 19. doi: 10.1002/cncr.34035.
    PubMed     Abstract available
    
    
    September 2021
12. KIRK PS, Zhu K, Zheng Y, Newcomb LF, et al
    Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer.
    Cancer. 2021 Sep 13. doi: 10.1002/cncr.33911.
    PubMed     Abstract available
    
    
    August 2021
13. PATEL HD, Koehne EL, Shea SM, Bhanji Y, et al
    Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: A prospective evaluation of the PLUM cohort.
    Cancer. 2021 Aug 24. doi: 10.1002/cncr.33875.
    PubMed     Abstract available
    
    
    
14. EZENWANKWO EF, Nnaji CA
    Prostate cancer and the added burden of COVID-19 in sub-Saharan Africa: Rethinking regional priorities for responsive and data-driven cancer control programs.
    Cancer. 2021 Aug 23. doi: 10.1002/cncr.33887.
    PubMed    
    
    
    
15. GARLAND SN, Savard J, Eisel SL, Wassersug RJ, et al
    A 2-year prospective analysis of insomnia as a mediator of the relationship between androgen deprivation therapy and perceived cognitive function in men with prostate cancer.
    Cancer. 2021 Aug 19. doi: 10.1002/cncr.33850.
    PubMed     Abstract available
    
    
    
16. NIERENGARTEN MB
    Health literacy may determine treatment choice for favorable-risk prostate cancer: Results from a new trial show that men with low health literacy are less likely to choose active surveillance for prostate cancer after genomic testing.
    Cancer. 2021;127:2825-2826.
    PubMed    
    
    
    
17. NECCHI A, Cucchiara V, Grivas P, Bratslavsky G, et al
    Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
    Cancer. 2021 Aug 11. doi: 10.1002/cncr.33865.
    PubMed     Abstract available
    
    
    
18. MEISSNER VH, Olze L, Schiele S, Ankerst DP, et al
    Fear of cancer recurrence and disease progression in long-term prostate cancer survivors after radical prostatectomy: A longitudinal study.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33836.
    PubMed     Abstract available
    
    
    
19. BERGEROT CD, Williams SB, Klaassen Z
    Fear of cancer recurrence among patients with localized prostate cancer.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33837.
    PubMed    
    
    
    
20. COURTNEY PT, Deka R, Kotha NV, Cherry DR, et al
    Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men.
    Cancer. 2021 Aug 4. doi: 10.1002/cncr.33824.
    PubMed     Abstract available
    
    
    July 2021
21. SERAPHIN TP, Joko-Fru WY, Hammerl L, Griesel M, et al
    Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: A population-based registry study.
    Cancer. 2021 Jul 30. doi: 10.1002/cncr.33818.
    PubMed     Abstract available
    
    
    
22. GREENBERG SA, Washington SL 3rd
    The state of our understanding of prostate cancer in sub-Saharan Africa.
    Cancer. 2021 Jul 30. doi: 10.1002/cncr.33815.
    PubMed    
    
    
    
23. FERRARO S, Rossi RS, Biganzoli EM
    Benefit-harm ratio of the diagnostic workup in patients with prostate cancer of Gleason score from 9 to 10.
    Cancer. 2021 Jul 23. doi: 10.1002/cncr.33811.
    PubMed    
    
    
    
24. KIM DW, Tilki D, D'Amico AV
    Reply to Benefit-harm ratio of the diagnostic workup in patients with prostate cancer and a Gleason score of 9 to 10.
    Cancer. 2021 Jul 23. doi: 10.1002/cncr.33813.
    PubMed    
    
    
    
25. PRINTZ C
    Prostate cancer in Black men responds better to immunotherapy.
    Cancer. 2021;127:2389.
    PubMed    
    
    
    
26. KIM DW, Chen MH, Wu J, Huland H, et al
    Prostate-specific antigen levels of 4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer.
    Cancer. 2021;127:2222-2228.
    PubMed     Abstract available
    
    
    
27. PATEL DC, He H, Berry MF, Yang CJ, et al
    Cancer diagnoses and survival rise as 65-year-olds become Medicare-eligible.
    Cancer. 2021;127:2302-2310.
    PubMed     Abstract available
    
    
    June 2021
28. RUDE T, Walter D, Ciprut S, Kelly MD, et al
    Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration.
    Cancer. 2021 Jun 29. doi: 10.1002/cncr.33643.
    PubMed     Abstract available
    
    
    
29. QUINN TP, Sanda MG, Howard DH, Patil D, et al
    Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer.
    Cancer. 2021 Jun 17. doi: 10.1002/cncr.33518.
    PubMed     Abstract available
    
    
    
30. MCMAHON GC, Leapman MS
    A disease by any other name: Effects of cancer grading nomenclature on perception of prostate cancer risk.
    Cancer. 2021 Jun 3. doi: 10.1002/cncr.33619.
    PubMed    
    
    
    
31. HUDNALL MT, Desai AS, Tsai KP, Weiner AB, et al
    It's all in the name: Does nomenclature for indolent prostate cancer impact management and anxiety?
    Cancer. 2021 Jun 3. doi: 10.1002/cncr.33621.
    PubMed     Abstract available
    
    
    
32. HOWARD DH, Quek RGW, Fox KM, Arondekar B, et al
    The value of new drugs for advanced prostate cancer.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33662.
    PubMed     Abstract available
    
    
    
33. PARIKH RB, Gallo JJ, Wong YN, Robinson KW, et al
    Long-term depression incidence and associated mortality among African American and White prostate cancer survivors.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33656.
    PubMed     Abstract available
    
    
    May 2021
34. HUNT TC, Ambrose JP, Haaland B, Kawamoto K, et al
    Decision fatigue in low-value prostate cancer screening.
    Cancer. 2021 May 27. doi: 10.1002/cncr.33644.
    PubMed     Abstract available
    
    
    
35. COLE AP, Herzog P, Iyer HS, Marchese M, et al
    Racial differences in the treatment and outcomes for prostate cancer in Massachusetts.
    Cancer. 2021 May 17. doi: 10.1002/cncr.33564.
    PubMed     Abstract available
    
    
    
36. GEORGE DJ, Halabi S, Heath EI, Sartor AO, et al
    A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
    Cancer. 2021 May 5. doi: 10.1002/cncr.33589.
    PubMed     Abstract available
    
    
    April 2021
37. BUTLER SS, Mahal BA, Moslehi JJ, Nohria A, et al
    Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
    Cancer. 2021 Apr 27. doi: 10.1002/cncr.33486.
    PubMed     Abstract available
    
    
    
38. BAUER JE
    Prostate cancer survivorship, deaths, and health care management.
    Cancer. 2021 Apr 21. doi: 10.1002/cncr.33588.
    PubMed    
    
    
    
39. WEINER AB, Li EV, Desai AS, Press DJ, et al
    Cause of death during prostate cancer survivorship: A contemporary, US population-based analysis.
    Cancer. 2021 Apr 21. doi: 10.1002/cncr.33584.
    PubMed     Abstract available
    
    
    
40. ONDERDONK BE, Dorn PL, Martinez C, Arif F, et al
    A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity.
    Cancer. 2021 Apr 21. doi: 10.1002/cncr.33556.
    PubMed     Abstract available
    
    
    
41. BITTERMAN DS, Chen MH, Wu J, Renshaw AA, et al
    Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality.
    Cancer. 2021 Apr 6. doi: 10.1002/cncr.33543.
    PubMed     Abstract available
    
    
    
42. ALIBHAI SMH, Breunis H, Hansen AR, Gregg R, et al
    Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer.
    Cancer. 2021 Apr 2. doi: 10.1002/cncr.33523.
    PubMed     Abstract available
    
    
    
43. IYER HS, Gomez SL, Chen JT, Trinh QD, et al
    Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position.
    Cancer. 2021 Apr 2. doi: 10.1002/cncr.33506.
    PubMed     Abstract available
    
    
    March 2021
44. CARAM MEV, Burns J, Kumbier K, Sparks JB, et al
    Factors influencing treatment of veterans with advanced prostate cancer.
    Cancer. 2021 Mar 25. doi: 10.1002/cncr.33485.
    PubMed     Abstract available
    
    
    
45. WILKINS LJ, Tosoian JJ, Reichard CA, Sundi D, et al
    Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.
    Cancer. 2021 Mar 15. doi: 10.1002/cncr.33419.
    PubMed     Abstract available
    
    
    
46. BRAWLEY OW
    Prostate cancer and the social construct of race.
    Cancer. 2021 Mar 15. doi: 10.1002/cncr.33417.
    PubMed    
    
    
    
47. KWON DH, Chou J, Yip SM, Reimers MA, et al
    Differential Treatment Outcomes in BRCA1/2-, CDK12-, and ATM-Mutated Metastatic Castration-Resistant Prostate Cancer.
    Cancer. 2021 Mar 10. doi: 10.1002/cncr.33487.
    PubMed     Abstract available
    
    
    February 2021
48. PASALIC D, Barocas DA, Huang LC, Zhao Z, et al
    Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
    Cancer. 2021 Feb 17. doi: 10.1002/cncr.33388.
    PubMed     Abstract available
    
    
    
49. NABI J, Tully KH, Cole AP, Marchese M, et al
    Access denied: The relationship between patient insurance status and access to high-volume hospitals.
    Cancer. 2021;127:577-585.
    PubMed     Abstract available
    
    
    
50. REITER-BRENNAN C, Dzaye O, Al-Mallah MH, Dardari Z, et al
    Fitness and prostate cancer screening, incidence, and mortality: Results from the Henry Ford Exercise Testing (FIT) Project.
    Cancer. 2021 Feb 9. doi: 10.1002/cncr.33426.
    PubMed     Abstract available
    
    
    
51. LEE RT, Kwon N, Wu J, To C, et al
    Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer.
    Cancer. 2021 Feb 1. doi: 10.1002/cncr.33324.
    PubMed     Abstract available
    
    
    January 2021
52. PRINTZ C
    Delaying radiation therapy for prostate cancer unlikely to affect survival during coronavirus disease 2019.
    Cancer. 2021;127:171.
    PubMed    
    
    
    
53. NGUYEN DD, Trinh QD, Cole AP, Kilbridge KL, et al
    Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States.
    Cancer. 2021;127:249-256.
    PubMed     Abstract available
    
    
    
54. LAUTZ TB, Chi YY, Li M, Wolden SL, et al
    Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group.
    Cancer. 2021;127:275-283.
    PubMed     Abstract available
    
    
    
55. GREGG JR, Zhang X, Chapin BF, Ward JF, et al
    Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort.
    Cancer. 2021 Jan 7. doi: 10.1002/cncr.33182.
    PubMed     Abstract available
    
    
    December 2020
56. HOOGLAND AI, Jim HSL, Gonzalez BD, Small BJ, et al
    Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findings.
    Cancer. 2020 Dec 30. doi: 10.1002/cncr.33397.
    PubMed     Abstract available
    
    
    
57. NAZHA B, Bilen MA
    Circulating interleukin 6, androgen deprivation therapy, and fatigue in prostate cancer: Is inflammation the link?
    Cancer. 2020 Dec 30. doi: 10.1002/cncr.33398.
    PubMed    
    
    
    
58. R BUSKBJERG C, Zachariae R, Buus S, H Gravholt C, et al
    Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in patients with newly diagnosed prostate cancer referred to androgen-deprivation therapy.
    Cancer. 2020 Dec 22. doi: 10.1002/cncr.33387.
    PubMed     Abstract available
    
    
    November 2020
59. SOHLBERG EM, Thomas IC, Yang J, Kapphahn K, et al
    Laboratory-wide association study of survival with prostate cancer.
    Cancer. 2020 Nov 25. doi: 10.1002/cncr.33341.
    PubMed     Abstract available
    
    
    
60. WASHINGTON SL 3RD, Master VA
    Health literacy and shared decision making in prostate cancer screening: Equality versus equity.
    Cancer. 2020 Nov 9. doi: 10.1002/cncr.33235.
    PubMed    
    
    
    October 2020
61. FILSON CP, Hong F, Xiong N, Pozzar R, et al
    Decision support for men with prostate cancer: Concordance between treatment choice and tumor risk.
    Cancer. 2020 Oct 29. doi: 10.1002/cncr.33241.
    PubMed     Abstract available
    
    
    
62. PAKARAINEN T, Nevalainen J, Talala K, Taari K, et al
    Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC).
    Cancer. 2020 Oct 13. doi: 10.1002/cncr.33254.
    PubMed     Abstract available
    
    
    
63. MCKAY RR, Sarkar RR, Kumar A, Einck JP, et al
    Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration.
    Cancer. 2020 Oct 9. doi: 10.1002/cncr.33224.
    PubMed     Abstract available
    
    
    
64. DEVILLE C JR, Lee WR
    Reconciling outcomes for Black men with prostate cancer within and outside the Veterans Health Administration.
    Cancer. 2020 Oct 9. doi: 10.1002/cncr.33225.
    PubMed    
    
    
    
65. SHOAG JE, Cai PY, Gross MD, Gaffney C, et al
    Reply to The risk factors of upgrading in prostate cancer.
    Cancer. 2020;126:4432-4433.
    PubMed    
    
    
    
66. CEKER G, Caliskan S
    The risk factors of upgrading in prostate cancer.
    Cancer. 2020;126:4432.
    PubMed    
    
    
    September 2020
67. LI CY, Chen LC, Lin HY, Lee MS, et al
    Impact of 23-valent pneumococcal polysaccharide vaccination on the frequency of pneumonia-related hospitalization and survival in elderly patients with prostate cancer: A seven-year nationwide matched cohort study.
    Cancer. 2020 Sep 30. doi: 10.1002/cncr.33203.
    PubMed     Abstract available
    
    
    
68. CARAM MEV, Oerline MK, Dusetzina S, Herrel LA, et al
    Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
    Cancer. 2020 Sep 14. doi: 10.1002/cncr.33176.
    PubMed     Abstract available
    
    
    
69. WEN W, Luckenbaugh AN, Bayley CE, Penson DF, et al
    Racial disparities in mortality for patients with prostate cancer after radical prostatectomy.
    Cancer. 2020 Sep 8. doi: 10.1002/cncr.33152.
    PubMed     Abstract available
    
    
    
70. KIM IE JR, Jang TL, Kim S, Modi PK, et al
    Abrogation of survival disparity between black and white individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
    Cancer. 2020 Sep 5. doi: 10.1002/cncr.33179.
    PubMed     Abstract available
    
    
    
71. PRINTZ C
    Prostate cancer mortality projections reach a new high: With prostate cancer deaths projected to rise to their highest level in 20 years, some experts worry that changes to screening guidelines made in 2012 could be a factor.
    Cancer. 2020;126:3893-3894.
    PubMed    
    
    
    July 2020
72. XU X, Fallah M, Tian Y, Mukama T, et al
    Risk of invasive prostate cancer and prostate cancer death in relatives of patients with prostatic borderline or in situ neoplasia: A nationwide cohort study.
    Cancer. 2020 Jul 22. doi: 10.1002/cncr.33096.
    PubMed     Abstract available
    
    
    
73. RIVIERE PJ, Rose BS
    Reply to Access and socioeconomic status play an important role in outcomes for African American patients with prostate cancer and Equal access to health care reduces racial disparities in prostate cancer outcomes.
    Cancer. 2020 Jul 9. doi: 10.1002/cncr.33064.
    PubMed    
    
    
    
74. LUNDON DJ, Dovey Z, Tewari AK
    Access and socioeconomic status play an important role in outcomes for African American patients with prostate cancer.
    Cancer. 2020 Jul 9. doi: 10.1002/cncr.33063.
    PubMed    
    
    
    
75. HOGE CG, Sussman J, Sidana A
    Equal access to health care reduces racial disparities in prostate cancer outcomes.
    Cancer. 2020 Jul 9. doi: 10.1002/cncr.33065.
    PubMed    
    
    
    June 2020
76. ITO K, Kobayashi M, Komiyama M, Naito S, et al
    Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
    Cancer. 2020 Jun 23. doi: 10.1002/cncr.33034.
    PubMed     Abstract available
    
    
    
77. DORES GM, Niu MT, Izurieta HS
    Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
    Cancer. 2020;126:2934-2935.
    PubMed    
    
    
    
78. HIGANO CS, Armstrong AJ, Sartor O, Vogelzang NJ, et al
    Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
    Cancer. 2020;126:2935-2937.
    PubMed    
    
    
    
79. PRINTZ C
    Price transparency still an issue for cancer center costs.
    Cancer. 2020;126:2733.
    PubMed    
    
    
    
80. VIDAL AC, Oyekunle T, Howard LE, De Hoedt AM, et al
    Obesity, race, and long-term prostate cancer outcomes.
    Cancer. 2020 Jun 4. doi: 10.1002/cncr.32906.
    PubMed     Abstract available
    
    
    
81. PRINTZ C
    First person profile: Maha Hussain, MD: Dr. Hussain's contributions to research on prostate cancer have led to major treatment advances.
    Cancer. 2020;126:2507-2508.
    PubMed    
    
    
    May 2020
82. HENLEY SJ, Thomas CC, Lewis DR, Ward EM, et al
    Annual report to the nation on the status of cancer, part II: Progress toward Healthy People 2020 objectives for 4 common cancers.
    Cancer. 2020;126:2250-2266.
    PubMed     Abstract available
    
    
    
83. TAKAHASHI TF
    The golden rule: Do not do to others what you do not want done to yourself.
    Cancer. 2020;126:2319-2320.
    PubMed    
    
    
    
84. PATEL DN, Howard LE, De Hoedt AM, Amling CL, et al
    Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer.
    Cancer. 2020 May 6. doi: 10.1002/cncr.32933.
    PubMed     Abstract available
    
    
    April 2020
85. WEINER AB, Vo AX, Desai AS, Hu JC, et al
    Changes in prostate-specific antigen at the time of prostate cancer diagnosis after medicaid expansion in young men.
    Cancer. 2020 Apr 28. doi: 10.1002/cncr.32930.
    PubMed     Abstract available
    
    
    
86. DALL'ERA MA, McPherson JD, Gao AC, DeVere White RW, et al
    Germline and somatic DNA repair gene alterations in prostate cancer.
    Cancer. 2020 Apr 21. doi: 10.1002/cncr.32908.
    PubMed     Abstract available
    
    
    February 2020
87. JOSHI SS, Filson CP
    Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening.
    Cancer. 2020;126:694-696.
    PubMed    
    
    
    November 2019
88. RAMIREZ AG, Choi BY, Munoz E, Perez A, et al
    Assessing the effect of patient navigator assistance for psychosocial support services on health-related quality of life in a randomized clinical trial in Latino breast, prostate, and colorectal cancer survivors.
    Cancer. 2019 Nov 19. doi: 10.1002/cncr.32626.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: